X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA JUBILANT LIFE SCIENCES TORRENT PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 37.2 18.5 200.7% View Chart
P/BV x 5.8 4.5 129.5% View Chart
Dividend Yield % 0.9 0.4 231.2%  

Financials

 TORRENT PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
JUBILANT LIFE SCIENCES
Mar-14
TORRENT PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,768187 946.4%   
Low Rs1,18665 1,821.2%   
Sales per share (Unadj.) Rs346.1364.3 95.0%  
Earnings per share (Unadj.) Rs55.26.8 805.9%  
Cash flow per share (Unadj.) Rs73.324.5 299.2%  
Dividends per share (Unadj.) Rs14.003.00 466.7%  
Dividend yield (eoy) %0.92.4 39.8%  
Book value per share (Unadj.) Rs257.1164.9 155.9%  
Shares outstanding (eoy) m169.22159.28 106.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.30.3 1,234.2%   
Avg P/E ratio x26.818.4 145.5%  
P/CF ratio (eoy) x20.15.1 391.8%  
Price / Book Value ratio x5.70.8 752.1%  
Dividend payout %25.443.8 57.9%   
Avg Mkt Cap Rs m249,88720,061 1,245.6%   
No. of employees `00011.86.2 190.5%   
Total wages/salary Rs m9,93411,052 89.9%   
Avg. sales/employee Rs Th4,971.59,383.0 53.0%   
Avg. wages/employee Rs Th843.21,786.9 47.2%   
Avg. net profit/employee Rs Th792.4176.3 449.5%   
INCOME DATA
Net Sales Rs m58,56958,034 100.9%  
Other income Rs m2,233191 1,171.6%   
Total revenues Rs m60,80258,224 104.4%   
Gross profit Rs m13,7735,786 238.0%  
Depreciation Rs m3,0692,812 109.2%   
Interest Rs m2,0563,237 63.5%   
Profit before tax Rs m10,881-72 -15,091.4%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,545696 221.9%   
Profit after tax Rs m9,3361,090 856.2%  
Gross profit margin %23.510.0 235.8%  
Effective tax rate %14.2-965.9 -1.5%   
Net profit margin %15.91.9 848.4%  
BALANCE SHEET DATA
Current assets Rs m53,84129,280 183.9%   
Current liabilities Rs m31,61238,912 81.2%   
Net working cap to sales %38.0-16.6 -228.7%  
Current ratio x1.70.8 226.3%  
Inventory Days Days9784 115.2%  
Debtors Days Days8451 165.3%  
Net fixed assets Rs m42,07955,712 75.5%   
Share capital Rs m846155 547.7%   
"Free" reserves Rs m42,65520,968 203.4%   
Net worth Rs m43,50126,265 165.6%   
Long term debt Rs m22,40817,169 130.5%   
Total assets Rs m101,25088,606 114.3%  
Interest coverage x6.31.0 643.7%   
Debt to equity ratio x0.50.7 78.8%  
Sales to assets ratio x0.60.7 88.3%   
Return on assets %11.34.9 230.4%  
Return on equity %21.54.2 516.9%  
Return on capital %19.611.6 169.7%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m20,06622,004 91.2%   
Fx outflow Rs m5,30411,749 45.1%   
Net fx Rs m14,76210,255 143.9%   
CASH FLOW
From Operations Rs m10,1278,026 126.2%  
From Investments Rs m-7,869-1,744 451.2%  
From Financial Activity Rs m-1,918-4,447 43.1%  
Net Cashflow Rs m2121,834 11.5%  

Share Holding

Indian Promoters % 71.5 45.6 156.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 7.0 8.7 80.7%  
FIIs % 12.6 21.2 59.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.1 41.7%  
Shareholders   26,511 23,815 111.3%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS